公告称，收入增加主要是由于于报告期内，集团的VitaFlow Liberty经导管主动脉瓣膜及可回收输送系统 在全球商业化方面的持续推进促进了海外收入的大幅增长;及集团的AnchorMan左心耳封堵系统及 AnchorMan左心耳导引系统在中国和海外的商业化进展稳步推进。 心通医疗-B(02160)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入2.29亿元，同比增加 2.67%;公司权益股东应占亏损216.3万元，同比减少96.17%;每股基本亏损0.09分。 ...

Core Viewpoint - The company, HeartFlow Medical-B (02160), is experiencing a decline in stock price ahead of its mid-year performance announcement, with a projected net loss for the first half of 2025 not exceeding RMB 10 million, representing a year-on-year decrease of at least 83% [1] Financial Performance - The company anticipates a significant reduction in net loss due to increased sales of the VitaFlow Liberty transcatheter aortic valve and delivery system in over 20 countries/regions, with overseas revenue more than doubling [1] - The commercial progress of the AnchorMan left atrial appendage occluder system and its guiding system in China is steady, and it has received CE marking for commercialization in Europe, contributing to revenue growth [1] Operational Efficiency - Continuous optimization of resource allocation has further enhanced operational efficiency [1] - The completion of D-round financing by the joint venture 4C Medical has resulted in a decrease in the company's shareholding, which is recognized as a gain from the sale of equity [1]

Core Viewpoint - HeartFlow Medical-B (02160) experienced a nearly 7% drop before earnings announcement, currently down 4.2% at HKD 1.37, with a trading volume of HKD 11.31 million [1] Financial Performance - The company plans to hold a board meeting on August 28 to approve its interim results [1] - HeartFlow Medical issued a profit warning, expecting a net loss of no more than RMB 10 million for the first half of 2025, representing a year-on-year decrease of no less than 83% [1] Revenue Drivers - The reduction in net loss is primarily attributed to the sales of the VitaFlow Liberty transcatheter aortic valve and its delivery system, which have been sold in over 20 countries/regions [1] - Revenue from overseas markets has increased by more than two times [1] - The commercial progress of the AnchorMan left atrial appendage occluder system and its guiding system in China is steadily advancing, with CE marking obtained for commercialization in Europe, contributing to revenue growth [1] Operational Efficiency - Continuous optimization of resource allocation has further enhanced operational efficiency [1] - The completion of D-round financing by the joint venture 4C Medical has resulted in a decrease in the company's shareholding, leading to recognized gains from the sale of equity [1]

（原标题：港股异动 | 心通医疗-B(02160)午前涨超4% 将于本月底发布业绩 预期上半年净亏损同比减少 不低于83%） 消息面上，心通医疗-B拟于8月28日举行董事会会议考虑及批准中期业绩。此前，心通医疗-B发布公 告，该集团预期2025年上半年取得净亏损不高于人民币1000万元，同比减少不低于83%。 公告称，净亏损减少主要是由于：VitaFlow Liberty经导管主动脉瓣膜及可回收输送系统已在海外20余个 国家╱地区实现销售，来自海外的收入同比增长两倍以上；AnchorMan左心耳封堵器系统及其导引系统 在中国的商业化进展稳步推进，并于报告期内获得CE标志并在欧洲实现商业化，共同贡献了收入增 量；集团通过持续优化资源配置、积极管控各项费用等措施进一步提升运营效率；及集团的联营公司 4C Medical Technologies, Inc完成D轮融资，集团于4C Medical的股权比例下降，获得视作出售部分股权 的收益。 智通财经APP获悉，心通医疗-B(02160)午前涨超4%，截至发稿，涨4.05%，报1.54港元，成交额1622.65 万港元。 ...

Core Viewpoint - HeartFlow Medical-B (02160) is expected to report a significant reduction in net loss for the first half of 2025, projecting a loss not exceeding RMB 10 million, which represents a year-on-year decrease of no less than 83% [1] Financial Performance - The company anticipates a net loss reduction primarily due to the sales of the VitaFlow Liberty transcatheter aortic valve and its retrievable delivery system, which has been sold in over 20 countries/regions, resulting in a year-on-year revenue increase of over 200% [1] - The AnchorMan left atrial appendage occluder system and its guiding system have made steady progress in commercialization in China, achieving CE marking and commercializing in Europe during the reporting period, contributing to revenue growth [1] Operational Efficiency - The company has improved operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The joint venture 4C Medical Technologies, Inc. completed a Series D financing round, leading to a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]

Company Overview - MicroPort CardioFlow Medtech Co., Ltd. is a leading innovative medical device company in the field of structural heart disease in China, originating from a valve pre-research project established in 2009 and listed on the Hong Kong Stock Exchange in February 2021 [2] - The company has successfully launched its self-developed transcatheter aortic valve implantation (TAVI) series and related surgical products in over 700 core hospitals across more than 20 countries and regions, treating over 10,000 patients with structural heart disease [2] - The VitaFlow Liberty transcatheter aortic valve and its reusable delivery system became the first domestically developed TAVI system to receive EU CE certification in 2024, accelerating the company's global strategic layout [2] Financial Performance - As of December 31, 2024, MicroPort CardioFlow reported total operating revenue of 362 million yuan, a year-on-year increase of 7.54% [1] - The net profit attributable to the parent company was -49.446 million yuan, showing a significant year-on-year increase of 89.51% [1] - The gross profit margin stood at 69.48%, with a debt-to-asset ratio of 16.97% [1] Market Position and Valuation - Currently, there are no institutional investment ratings for MicroPort CardioFlow [1] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.24 times, with a median of 1.4 times [1] - MicroPort CardioFlow's P/E ratio is -61 times, ranking 61st in the industry, compared to other companies such as Jingjiu Medical (0.38 times), Star Medical Holdings (0.45 times), and others [1]